Signal Transduction of Pain: Implications for Opioid Therapy CME

Gavril W. Pasternak, MD, PhD; Charles E. Inturrisi, PhD; Frank Porreca, PhD; Michael C. Rowbotham, MD Author Information and Disclosures

Release Date: January 3, 2008; Valid for credit through January 3, 2009

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

This program is based on a luncheon Satellite Symposium held in conjunction with the 26th Annual Meeting of the American Pain Society, May 3, 2007, in Washington, DC.

To participate in this activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 MediCom Worldwide, Inc.
Cephalon
Learning Objectives

At the conclusion of this educational activity, participants should be able to:

  • Recognize the molecular mechanisms involved with analgesic opioid use in chronic pain therapy;
  • Identify emerging data in the development and understanding of the role and function of NMDA receptors in chronic pain;
  • Understand the mechanism and location of action of opioid pain medications;
  • Understand the various types of opioid delivery systems and the clinical indications for each.
Author Disclosures

Gavril Pasternak, MD, PhD - Chairman
Disclosure: Advisor: Dr. Gavril Pasternak has received consultant fees, as well as honoraria related to formal advisory activities from sanofi-aventis U.S. LLC; Ortho Biotech Products, L.P.; Endo Pharmaceuticals; Adolor Corporation; and Janssen, L.P.


Charles E. Inturrisi, PhD
Disclosure: Dr. Charles Inturrisi has disclosed that he has no significant relationships with the grantor Cephalon, Inc. or any other commercial company whose products and services may be related to his presentation.


Frank Porreca, PhD
Disclosure: Dr. Frank Porreca ha disclosed that he has no significant relationships with the grantor Cephalon, Inc. or any other commercial company whose products and services may be related to his presentation.


Michael C. Rowbotham, MD
Disclosure: Dr. Michael Rowbotham has disclosed that he has no significant relationships with the grantor Cephalon, Inc. or any other commercial company whose products and services may be related to his presentation.
 
MediCom Worldwide, Inc.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

MediCom Worldwide, Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.